Maddie Gilsenan

Aug 1, 2023 | onlinelibrary.wiley.com | David Hughes |Eden C. Andrew |Maddie Gilsenan |Cristina Mignone

Summary CD19-directed chimeric antigen receptor (CAR) T-cell therapy is an important therapy for relapsed or refractory acute lymphoblastic leukaemia, but its use carries the risk of immune effector cell-associated neurotoxicity syndrome (ICANS). In children, severe ICANS is almost universally reported in association with cytokine release syndrome and is reversible.